Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): ...Read More
Dr. Fakih is a paid consultant for Amgen.
We’re sorry, the page you were trying to view cannot be found.
It may be the result of either a mistyped address or an out-of-date link.
IMPORTANT SAFETY INFORMATION
Please see Vectibix® full Prescribing Information, including Boxed WARNINGBoxed WARNING.
Indication
Vectibix® is indicated for the treatment of patients with wild‑type RAS (defined as wild‑type in both KRAS and NRAS as determined by an FDA‑approved test for this use) metastatic colorectal cancer (mCRC):
Limitation of Use
Vectibix® is not indicated for the treatment of patients with RAS‑mutant mCRC or for whom RAS mutation status is unknown.